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Abstract
The Chaga mushroom (Inonotus obliquus) has been used in folk medicine to treat cancers. However, limited information exists on the underlying
anticancer effects of the major component of I. obliquus  in vivo. We hypothesize that the pure compounds (3β-hydroxy-lanosta-8,24-dien-21-al,
inotodiol and lanosterol, respectively) separated from I. obliquus would inhibit tumor growth in Balbc/c mice bearing Sarcoma-180 cells (S-180)
in vivo and growth of human carcinoma cells in vitro. To test this hypothesis, the growth inhibition of each subfraction isolated from I. obliquus
on human carcinoma cell lines (lung carcinoma A-549 cells, stomach adenocarcinoma AGS cells, breast adenocarcinoma MCF-7 cells, and cervical
adenocarcinoma HeLa cells) was tested in vitro. Then, after S-180 implantation, the mice were fed a normal chow supplemented with 0, 0.1 or 
0.2 mg of subfraction 1, 2 or 3 per mouse per day. All of the subfractions isolated from I. obliquus showed significant cytotoxic activity against 
the selected cancer cell lines in vitro. Subfraction 1 was more active than subfraction 2 and subfraction 3 against the A549, AGS and MCF-7
cancer cell lines in vitro. In in vivo results, subfraction 1 isolated from I. obliquus at concentrations of 0.1 and 0.2 mg/mouse per day significantly
decreased tumor volume by 23.96% and 33.71%, respectively, as compared with the control. Subfractions 2 and 3 also significantly inhibited tumor
growth in mice bearing S-180 as compared with the control mouse tumor. Subfraction 1 isolated from I. obliquus showed greater inhibition of
tumor growth than subfractions 2 and 3, which agrees well with the in vitro results. The results suggest that I. obliquus and its compounds in
these subfractions isolated from I. obliquus could be used as natural anticancer ingredients in the food and/or pharmaceutical industry.
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Introduction1)
Most chemotherapeutic agents for the treatment of cancer can 
destroy tumors and arrest cancer progress [1] but cancer treatment 
may damage healthy cells and tissues. Thus, new anticancer drugs 
from natural products are expected to play an important role in 
the development of more effective and safer agents to inhibit 
the onset of cancer [1].
  Roland  et al. [2] first isolated the 
anticancer factor calvaine from the basidiomycete Calvatia 
gigantea, which has long been used as a medicinal food. Almost 
50 species in 20 generi of mushrooms have been identified as 
having anticancer activity [3]. The Chaga mushroom (Inonotus 
obliquus) has been used medicinally for treating cancer in several 
regions of the world [4].
Many studies have reported that I. obliquus contains excellent 
bioactive compounds [5,6]. 3β-Hydroxy-lanosta-8,24-dien-21-al 
has been identified from I. obliquus [7], and a high-molecular- 
weight, water-soluble, lignin-like substance from edible mushrooms 
of I. obliquus has been reported to inhibit the protease of type-1 
human immunodeficiency virus [8].
  Inotodiol isolated from the 
sclerotia of I. obliquus has been reported to have an inhibitory 
effect in a two-stage carcinogenesis test on mouse skin using 
7,12-dimethyl-benz[α]anthracene [9].
  Lee et al. [10] reported that 
a hot-water extract of I. obliquus exerts inhibitory activity against 
the proliferation of human colon cancer cells (HT-29). We 
recently identified subfractions 1 and 2 as 3β-hydroxy-lanosta- 
8,24-dien-21-al and inotodial, respectively and have reported that 
the compounds have antimutagenic and antioxidative activities 
[11]. We also found that subfraction 3 has antimutagenic and 
antioxidative activities (unpublished results). Oxidative stress and 
mutagenic activity play important roles in the cancer process [12]. 
Thus, the possibility exists that subfractions 1, 2, and 3 also have 
anticancer activity in vitro against the proliferation of human 
cancer cells and in vivo against sarcoma growth in a mouse 
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Fig. 1. Preparation of Inonotus obliquus subfractions
model. There may also be anticancer activity of subfractions 
containing pure compounds of I. obliquus extract in Balbc/c mice 
bearing Sarcoma-180 cells and in various cancer cell lines that 
have not been examined. Therefore, we hypothesized that the 
subfractions 1, 2 and 3 containing pure compounds (3β-hydroxy- 
lanosta-8,24-dien-21-al, inotodiol and lanosterol, respectively) 
separated from I. obliquus would inhibit tumor growth in mice 
bearing Sarcoma-180 cells (S-180) and as well as the growth 
of human carcinoma cell lines. The objective of this study was 
to test the activities of the three subfractions isolated from I. 
obliquus  against the proliferation of cancer cells and on solid 
tumor inhibition as a trial for the development of novel functional 
anticancer medicinal food and anticancer drugs. In this study, 
we contributed more information about natural anticancer 
compounds separated from I. obliquus for the prevention or/and 
treatment of human cancer.
Materials and Methods
Chemicals and reagents
Fetal bovine serum (FBS), 3-[4,5-dimethylthiazole-2-yl]-2,5- 
diphenyltetrazolium bromide (MTT), and dimethylsulfoxide 
(DMSO) were purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). RPMI1640 medium, penicillin and streptomycin 
(PEST), and trypsin-ethylenediaminetetraacetic acid (T-EDTA) 
were obtained from GibcoBRL (Gaithersburg, MD, USA). All 
solvents used were analytical grade.
Preparation of three subfractions from I. obliquus extracts
The subfractions from I. obliquus extracts were collected by 
the method of Ham et al. [11]. The I. obliquus specimen used 
in this study was imported from Russia, dried, powdered, and 
stored at -20℃. The powdered specimen (500 g) was extracted 
twice with 3 L of methanol (99.8%) at 45-50℃ for 3 h. The 
methanol fraction (45 g) was then rotary evaporated, emulsified, 
dissolved in water, and extracted three times with ethyl acetate 
(H2O:EtOAc, 5:7, v/v). The ethyl-acetate fraction (12 g) was 
obtained after rotary evaporation, and the dried extract was 
reconstituted in methanol. This stock solution was subjected to 
vacuum chromatography (N-2N; Eyela, Tokyo, Japan) with silica 
gel (60 g, 230-400 mesh) mixed with dichloromethane. The 
mobile phases were dichloromethane (A) and methanol (B), with 
a gradient of increasing methanol (0-100%) in dichloromethane 
and re-equilibration of the column with 100% A for 3 min prior 
to the next run (Fig. 1). The success of the fractionation was 
confirmed by thin-layer chromatography (TLC). Based on the 
Ames test and the DPPH method, amongst the three ethyl- 
acetate-extract fractions, VCHG-fraction 1 was the most bioactive 
fraction in the antimutagenic and antioxidant effects [5,6]. Thus, 
the VCHG-fraction 1 was selected and subjected to column 
chromatography using a reversed-phase column (ODS-C18) 
containing LiChroprep RP-18 (25-40 μm) mixed with H2O: 
MeOH (1:30, v/v) in a gradient program ranging from 30% to 
100% methanol (mobile phase A: methanol; mobile phase B: 
ultra-pure water). Four fractions were isolated, of which fraction 
2 exhibited the most bioactivity. Fraction 4 also had strong 
bioactivity. Fraction 2 and fraction 4 were further fractionated 
by chromatography with a normal-phase column (2.4 cm×15 cm) 
containing silica gel (200 g, 70-230 mesh; Merck Co., Darmstadt, 
Germany) mixed with dichloromethane and eluted with a 
mobile-phase gradient ranging from 100% dichloromethane to 
50% methanol. The flow rate was 1.0 ml/min (Fig. 1). This 
resulted into two subfractions from fraction 2, designated as 
subfractions 1 and 2, both of which showed bioactivity. In our 
previous study, subfractions 1 and 2 were identified as 3β
-hydroxy-lanosta-8,24-dien-21-al and inotodiol, respectively [11]. 
Subfraction 3 was obtained from fraction 4 (Fig. 1). The 
compound in subfraction 3 was crystallized and characterized 
by determining its mass spectrometry (MS) (JEOL), 
1H nuclear 
magnetic resonance (
1H NMR), and 
13C nuclear magnetic 
resonance (
13C NMR) (Bruker DRX 500 MHz) spectra.
Cancer cell and normal cell lines
The human cancer cells used in this experiment were lung 
carcinoma A-549 cells, breast adenocarcinoma MCF-7 cells, 
stomach adenocarcinoma AGS cells, Sarcoma-180 cells, and 
cervical adenocarcinoma HeLa cells. These, and the normal 
transformed primary human embryonic kidney (HEK) 293 cell 
line, were obtained from the Korean Cell Line Bank (Seoul, Mi Ja Chung et al. 179
Table 1. In vitro anticancer activity against human cancer cell lines (A549, AGS,
MCF-7, HeLa)
1) and normal human embryonic kidney (HEK) 293 cells of 
subfractions separated from Inonotus obliquus
SF
2) Dose 
(μg/mL)
Inhibition ratio (%)
A549 AGS MCF-7 HeLa HEK 293
SF 1 0 0.0 ± 2.3
a 0.0 ± 1.3
a 0.0 ± 1.3
a 0.0 ± 1.4
a 0.0 ± 1.5
a
62.5 21.4 ± 1.7
c 18.5 ± 0.7
b 42.1 ± 1.7
g 11.0 ± 1.2
b 15.4 ± 1.0
cd
125.0 25.4 ± 0.6
d 41.4 ± 1.0
e 57.3 ± 1.8
i 26.4 ± 1.9
d 16.5 ± 0.6
de
187.5 50.9 ± 2.3
gh 55.0 ± 1.3
h 65.6 ± 1.0
j 60.4 ± 1.0
h 19.9 ± 1.0
h
250.0 66.7 ± 1.5
i 72.2 ± 2.2
j 67.4 ± 0.8
j 69.5 ± 1.1
i 20.0 ± 1.4
h
SF 2 62.5 18.3 ± 1.1
b 28.2 ± 1.3
c 22.2 ± 1.5
c 18.4 ± 0.9
c 11.5 ± 0.9
b
125.0 20.5 ± 1.5
bc 31.4 ± 1.4
d 40.1 ± 1.2
g 30.3 ± 1.6
e 20.0 ± 0.6
h
187.5 49.2 ± 1.3
fg 45.1 ± 1.4
f 54.5 ± 1.3
h 42.5 ± 2.0
f 19.4 ± 0.8
gh
250.0 51.7 ± 0.7
h 51.0 ± 1.2
g 55.1 ± 1.3
hi 58.3 ± 1.9
h 19.0 ± 0.6
fgh
SF 3 62.5 19.1 ± 0.9
bc 20.0 ± 1.9
b 10.7 ± 1.3
b 17.4 ± 1.0
c 14.8 ± 0.7
cd
125.0 20.2 ± 1.0
bc 28.9 ± 0.9
c 25.4 ± 2.0
d 28.3 ± 0.9
de 14.3 ± 0.9
c
187.5 38.8 ± 0.8
e 67.5 ± 1.0
i 28.5 ± 1.0
e 51.3 ± 1.1
g 17.4 ± 1.5
ef
250.0 48.4 ± 0.7
f 56.9 ± 1.3
h 37.6 ± 2.2
f 71.2 ± 2.0
i 17.9 ± 0.8
efg
Data  are  presented  as  means ± SD  of  four  experiments. 
Values  with  different  superscripted  letters  (a-j)  within  the  same  column  are 
significantly  different  (P < 0.05)  as  determined  by  Duncan’s  multiple-range  test.
1) A549,  AGS,  MCF-7  and  HeLa  were  lung  carcinoma  A549  cells,  breast 
adenocarcinoma MCF-7 cells, stomach adenocarcinoma AGS cells and cervical 
adenocarcinoma  HeLa  cells,  respectively.
2) Subfraction 
Korea). All cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS and 1% PN/ST. The cells were 
incubated at 37℃ in a humid atmosphere containing 5% CO2.
Anticancer activity in vitro
The cytotoxic potential of the subfractions was evaluated by 
the MTT assay [12] against four human tumor cell lines: A549, 
MCF-7, AGS, and HeLa. The inhibitory activity against the 
proliferation of cancer cell lines was compared with that against 
the normal transformed primary human 293 cell line. The cells 
were seeded in 96 wells at a density of 5×10
4  cells/ml and 
cultured for 24 h in RPMI 1640 medium with 10% FBS and 
1% PEST at 37℃, 5% CO2.  The three subfractions separated 
from I. obliquus were dissolved in DMSO, and the stock solutions 
were diluted with RPMI 1640 medium (DMSO concentration <
0.01%). The DMSO was added to all test solutions at a final 
concentration of 0.01%. The control was the well containing 
0.01% DMSO only. Various concentrations of the subfractions 
(0, 62.5, 125.0, 187.5, and 250.0 μg/ml) were added to each 
culture well and incubated for 48 h. The supernatants were then 
removed by aspiration, and MTT (5 mg/ml) was added to each 
culture well (one-tenth of the original culture volumes). After 
incubation for 4 h, the medium was removed, and the cells were 
allowed to dry for 30 min. The precipitates were then solubilized 
in DMSO with shaking for 30 min. The extent of the reduction 
of MTT was quantified by measuring the absorbance at 570 nm.
In vivo anticancer assays
Anticancer activity in vivo against sarcoma growth in a mouse 
model was examined using the method of Ham et al. [13] and 
Maeda et al. [14] with minor modification. Briefly, Balbc/c mice 
(six-to seven-weeks-old) were obtained from Samtaco (Gyeonggi- 
do, Korea), randomly divided into the control and six 
experimental groups, and provided with water and normal chow. 
Animals were housed in an air-conditioned room at 21-26℃ with 
45-55% moisture and a 12-hour dark/light cycle. The mice were 
treated in accordance with Kangwon National University 
guidelines for the care and use of laboratory animals. The 
Sarcoma-180 cell line was cultured for 7-10 days in the 
abdominal cavity of a Balbc/c mouse, and the cultured cells were 
harvested with the peritoneal fluid and centrifuged at 1,200 rpm 
for 10 min in phosphate-buffered saline (PBS). The separated 
sarcoma cells were floated in PBS and centrifuged, and their 
concentration was adjusted to 1.0×10
6  cells/ml. The cells (0.2 
ml) were implanted subcutaneously in the left groins of mice. 
After 24 h, the mice were fed normal chow supplemented with 
water (control group), 0.1 mg subfraction 1 per mouse per day 
(S-180+subfraction 1A), 0.2 mg subfraction 1 per mouse per day 
(S-180+subfraction 1B), 0.1 mg subfraction 2 per mouse per day 
(S-180+subfraction 2A), 0.2 mg subfraction 2 per mouse per day 
(S-180+subfraction 2B), 0.1 mg subfraction 3 per mouse per day 
(S-180+subfraction 3A) or 0.2 mg subfraction 3 per mouse per 
day (S-180+subfraction 3B) for 20 days. The mice were fed 
normal chow for 7 days after the last oral administration of 
subfractions and then euthanized with an ip injection of Avertin 
(Sigma-Aldrich Co., St. Louis, MO, USA) [15] on the 27
th day 
after cancer-cell implantation. Solid tumors were removed and 
weighed, and the tumor-growth-inhibition ratio (I.R.) was 
calculated using the following formula:
I.R. (%) = (Cw-Tw)/Cw×100 
Cw: Average tumor weight of the control.
Tw: Average tumor weight of the experimental group.
Statistical analysis
The data were expressed as means ± SD. Differences between 
the groups were determined by one-way Analysis of Variance 
using the SPSS package (Version 10.0; SPSS, Chicago, IL, USA). 
The level of statistical significance was set at P<0.05. The 
comparisons of cancer cell growth inhibition in vitro and solid 
tumor growth inhibition in vivo among the groups were 
performed using Duncan’s multiple range test [15].
Results
Inhibition of cancer cell growth in vitro
As shown in Fig. 1, the ethyl-acetate fraction from I. obliquus 
was separated into three fractions by vacuum chromatography. 
VCHG-fraction 1 was further separated into four fractions by 180 Anticancer activity of Chaga mushroom
Table 2. Antitumor activity of the three subfractions separated from Inonotus obliquus in Balbc/c mice bearing Sarcoma-180 cells (S-180)
S-180＋water 
(control)
S-180＋subfraction 
1A
S-180＋subfraction 
1B
S-180＋subfraction 
2A
S-180＋subfraction 
2B
S-180＋subfraction 
3A
S-180＋subfraction 
3B
Tumor weight (g) 4.02 ± 0.19
e 3.06 ± 0.22
b 2.67 ± 0.34
a 3.75 ± 0.25
de 3.28 ± 0.31
bc 3.47 ± 0.23
cd 3.10 ± 0.13
b
Inhibition rate (%) 0.00 ± 4.64
a 23.96 ± 5.45
d 33.71 ± 8.49
e 6.67 ± 6.16
ab 18.45 ± 7.81
cd 13.60 ± 5.69
bc 22.97 ± 3.24
d
Values  are  means ± SD  of  six  mice. 
Values  with  different  superscripted  letters  (a-e)  within  the  sam e  r o w  a r e  s ig n if i c a n t l y  d i f f e r e n t  (P < 0.05)  as  determined  by  Duncan’s  multiple-range  test. 
The Sarcoma-180 cells were implanted subcutaneously in the left groins of mice. After 24 h, the mice were fed normal chow supplemented with water (S-180+water, control), 
0.1 mg of subfraction 1 per mouse per day (S-180+subfraction 1A), 0.2 mg of subfraction 1 per mouse per day (S-180+subfraction 1B), 0.1 mg of subfraction 2 per mouse 
per day (S-180+subfraction 2A), 0.2 mg of subfraction 2 per mouse per day (S-180+subfraction 2B), 0.1 mg of subfraction 3 per mouse per day (S-180+subfraction 3A) 
or 0.2 mg of subfraction 3 per  mouse per  day (S-180+subfraction 3B) for 20 days.  The  mice  were fed  normal chow for seven  days  after the last oral administration  of 
subfractions.  Solid  tumors  were  removed  on  the  27th  day  after  cancer  cell  implantation.
Fig. 2. Morphology of antitumor activity of subfraction 1 from Inonotus obliquus
on mice bearing Sarcoma-180 cells (S-180).  The  Sarcoma-180  cells  were 
implanted subcutaneously in the left groins of mice. After 24 h, the mice were fed 
normal chow supplemented with water (S-180+water, control), 0.1 mg subfractions 
1 per mouse per day (S-180+subfraction 1A) or 0.2 mg subfractions 1 per mouse 
per day (S-180+subfraction 1B) for 20 days. The mice were fed normal chow for 
seven  days  after  the  last  oral  administration  of  subfractions.  Solid  tumors  were 
r e m o v e d  o n  t h e  2 7
th day  after  cancer  cell  implantation.
reversed-phase (ODS-C18) column chromatography, of which the 
second fraction showed the greatest in vitro anticancer activity. 
Fraction 4 also had inhibitory activity against the proliferation 
of human cancer cells (data not shown). Fractions 2 and 4 from 
VCHG-fraction 1 were, in turn, separated by normal-phase 
silica-gel column chromatography into subfraction 1, subfraction 
2 and subfraction 3, respectively. Each of the three subfractions 
yielded a single spot by TLC, confirming single-compound purity 
(data not shown). Purity was also confirmed by MS, 
1H NMR, 
and 
13C NMR analyses. Each of compounds 1, 2, and 3 
(subfractions 1, 2, and 3) had a purity of above 99.5%. The pure 
compounds were assayed against human lung carcinoma A549, 
breast adenocarcinoma MCF-7, stomach adenocarcinoma AGS, 
and cervical adenocarcinoma HeLa cells and normal HEK 293 
cell line.
Exposure of normal HEK 293 cell culture to 0-250 μg/ml of 
subfractions for 48 h resulted in low cytotoxicity (Table 1), but 
high cytotoxicity was observed at a concentration of 300 μg/ml 
subfractions (data not shown). Thus, to avoid high cytotoxicity 
in normal cells from subfractions, 0-250 μg/ml subfractions were 
chosen for in vitro study.
As shown in Table 1, subfraction 1 was more active than 
subfraction 2 or subfraction 3 against the selected tumor cell 
lines A549, AGS, MCF-7, and HeLa. Subfractions 1, 2, and 3 
(250 μg/ml) inhibited the growth of A549 cells by 66.7%, 51.7%, 
and 48.4%, respectively, and inhibited that of AGS cells by 
72.2%, 51.0%, and 56.9%, respectively (Table 1). Subfractions 
1, 2, and 3 (250 μg/ml) inhibited the growth of MCF-7 cells 
by 67.4%, 55.1%, and 37.6%, respectively, and inhibited that 
of HeLa cells by 69.5%, 58.3%, and 71.2%, respectively (Table 
1). In contrast, the subfractions inhibited the growth of normal 
HEK 293 cells by less than 20% (Table 1). The results indicate 
that these subfractions inhibit cancer cell growth and have low 
cytotoxicity against normal cells.
Solid tumor growth inhibition
In our previous study, after oral administration with 0, 0.2, 
0.4, 0.8 or 1.6 mg ethyl acetate extract from I. obliquus per mouse 
per day, no genotoxic activity was observed, and the extract inhibited 
the genotoxic activity by N-methyl-N'-nitro-N-nitrosoguanidine 
in a dose-dependent manner [6]. Thus, to avoid toxicity from 
the subfractions, oral administration of 0.1 mg per mouse per 
day and that of 0.2 mg per mouse per day were chosen for in 
vivo experiment.
The average tumor weight of the Sarcoma-180-cell-bearing 
mice after water feeding (control) was 4.02 ± 0.19 g, whereas 
that of the mice after subfraction 1 administration at low level 
(0.1 mg/mouse per day, S-180+subfraction 1A) was 3.06 ± 0.22 
g and that of the mice after subfraction 1 feeding at high level 
(0.2 mg/mouse per day, S-180+subfraction 1B) was 2.67 ± 0.34 
g (Table 2). Thus, subfraction 1 at high level inhibited tumor 
weight by 33.71% of the control tumor weight, and treatment 
following tumor transplant resulted in a dose-dependent reduction 
of tumor weight in comparison with the untreated control (Fig. 
2). Subfraction 2 at high level (0.2 mg/mouse per day) and 
subfraction 3 at both low and high levels (0.1 mg/mouse per 
day and 0.2 mg/mouse per day, respectively) also inhibited solid 
tumor growth significantly (Table 2). Subfraction 1 showed much 
greater inhibition of tumor growth than subfractions 2 and 3 in 
the mice bearing Sarcoma-180 cells, in agreement with our in 
vitro results.
Structural analysis of I. obliquus subfraction 3
As shown in Fig. 1, the subfractions containing pure compounds 
were obtained after reversed-phase (ODS-C18) column chromato-Mi Ja Chung et al. 181
graphy of the ethyl-acetate extract of I. obliquus, followed by 
normal-phase silica-gel column chromatography. In our previous 
study, subfractions 1 and 2 were identified by MS, 
1H NMR, 
and 
13C NMR analyses as 3β-hydroxy-lanosta-8,24-dien-21-al 
and inotodiol, respectively [11].
Inotodiol and lanosterol have similar chemical structures. 
Inotodiol has an OH group at position 22 (C-22) of lanosterol 
[9]. The chemical structure of the compound in subfraction 3 
was determined by comparing the MS, 
1H-NMR, and 
13C-NMR 
spectra (data not shown) to published library spectra and spectra 
in the literature [7,9,15,16]. These analyses revealed that 
subfraction 3 is lanosterol. Thus, 3β-hydroxy-lanosta-8,24-dien- 
21-al, inotodiol, and lanosterol are bioactive compounds of I. 
obliquus with anticancer properties.
Discussion
This is the first study to report an antitumor effect of three 
subfractions (3β-hydroxy-lanosta-8,24-dien-21-al, inotodiol, and 
lanosterol) from I. obliquus extracts in the Sarcoma-180-cell- 
bearing mice and various cancer cell lines.
All of the subfractions showed significant inhibitory activity 
against the proliferation of the selected cancer cell lines (A549, 
AGS, MCF-7, and HeLa), but these subfractions have low 
cytotoxicity against normal cells. The subfractions inhibited cell 
growth in a dependent manner. Subfraction 1 was more active 
than subfraction 2 and subfraction 3 against the selected cancer 
cell lines. In our earlier study, ethanol extract from the I. obliquus 
showed high inhibition of the proliferation of A549, AGS, and 
MCF-7 cancer cells [5]. In another recent study, Lee et al. [10] 
reported that a hot-water extract of I. obliquus exerted inhibitory 
activity against the proliferation of human colon cancer cells 
(HT-29), in good agreement with our results.
Subfractions 1, 2 and 3 significantly inhibited tumor growth 
in mice bearing Sarcoma-180 cells as compared with the control 
mouse tumor, and subfraction 1 showed greater inhibition of 
tumor growth than did subfractions 2 and 3, in agreement with 
our in vitro results. Polysaccharides extracted from mycelia of 
I. obliquus not only reduce tumor size [17], but also lower 
elevated blood glucose [18]. Nakata et al. [9]
  have reported that 
the most abundant triterpene in I. obliquus, inotodiol, exhibits 
potent antitumor-promoting activity in a two-stage carcinogenesis 
test on mouse skin. This observation is consistent with our 
observations. Thus, subfractions of I. obliquus extracts have a 
strong anticancer effect and may be useful as an ingredient in 
functional anticancer food.
In this and previous studies, subfractions 1, 2 and 3 were 
identified by MS, 
1H NMR, and 
13C NMR analyses as 3β
-hydroxy-lanosta-8,24-dien-21-al, inotodiol [11] and lanosterol, 
respectively. Our observations are consistent with those of other 
studies [7,9,11,15,16,19] reported that inotodiol had an in vivo 
antitumor effect against P388-bearing mice. Inonotus obliquus 
appears to have an abundance of triterpenes, including lanosterol 
and inotodiol [9].
  A chloroform extract from I. obliquus has an 
antiproliferative effect on human cancer cell lines [19], and 
inotodiol is the main constituent of this chloroform extract [9].
 
Kahlos  et al. [18] reported that lanosterol and 3β-hydroxy- 
lanosta-8,24-dien-21-al also inhibit proliferation of MCF-7 
adenocarcinoma cells.
Lee et al. [10] showed that the hot water extract of Inonotus 
obliquus would be useful as an antitumor agent via the induction 
of the apoptosis and inhibition of the growth of cancer cells 
through up-regulation of the expression of proapoptotic proteins 
(Bax and caspase-3) and down-regulation of antiapoptotic 
proteins (Bcl-2). The water extract of Inonotus obliquus mushroom 
exhibited a potential anticancer activity against B16-F10 
melanoma cells in vitro and in vivo through the inhibition of 
proliferation and induction of differentiation and apoptosis of 
cancer cells [20]. Nomura et al. [19] reported that Inotodiol, from 
Inonotus obliquus, inhibits cancer cell proliferation through 
apoptosis induction by activating caspase-3. However, the 
mechanisms on anticancer activity of 3β-hydroxy-lanosta-8,24- 
dien-21-al and lanosterol have not been examined.
In conclusion, the three subfractions (3β-hydroxy-lanosta-8,24- 
dien-21-al, inotodiol, and lanosterol) inhibited in vitro 
proliferation of various human cancer cell lines. The three 
subfractions also had in vivo antitumor effects on Sarcoma-180- 
cell-bearing mice. 3β-hydroxy-lanosta-8,24-dien-21-al, inotodiol, 
and lanosterol may therefore be interesting compounds for the 
development of novel anticancer drugs and functional anticancer 
food. However, further human studies are needed to determine 
whether dietary feeding of 3β-hydroxy-lanosta-8,24-dien-21-al, 
inotodiol, and lanosterol can reduce tumor growth as observed 
in the present in vitro and  in vivo studies. We also need 
mechanistic studies on 3β-hydroxy-lanosta-8,24-dien-21-al and 
lanosterol.
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